Adjunctive Treatment of Major Depressive DisorderPhase 2NCT03018340
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
A Phase 2 study testing Pimavanserin in people with Adjunctive Treatment of Major Depressive Disorder, run by ACADIA Pharmaceuticals Inc. at 36 sites in United States.
Trial summary
To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) and an inadequate response to antidepressant therapy Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Adjunctive Treatment of Major Depressive Disorder
- What is being tested?
- Pimavanserin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 207 participants
- Where
- 36 sitesUnited States
- Study dates
- Dec 2016to Oct 2018
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients, aged 18 years and above
- A clinical diagnosis of major depressive disorder (MDD)
- Is being treated with one of the following SSRI or SNRI antidepressants as monotherapy:
- Citalopram
- Escitalopram
- Paroxetine
Show all 13Show fewer
- Fluoxetine
- Sertraline
- Duloxetine
- Venlafaxine
- Desvenlafaxine
- Venlafaxine XR
- Has a history of inadequate response to antidepressant treatments
Who cannot join
- Patient has a psychotic disorder other than MDD
- Patient has current evidence of a serious and/or unstable neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program
- Patient has a history or symptoms of long QT syndrome
- Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).
Trial locations and contacts
36 sites in 1 country.
36 sites in 1 country
United States36 sites
Emory University School of Medicine
Atlanta, Georgia, 30329
Hassman Research Institute
Berlin, New Jersey, 08009
UAB
Birmingham, Alabama, 35294
Meridien Research
Bradenton, Florida, 34201
Neuro-Behavioral Clinical Research
Canton, Ohio, 44718
Carolina Clinical Trials, Inc.
Charleston, South Carolina, 29407
Alam Medical Research, INC
Chicago, Illinois, 60612
Ericksen Research & Development
Clinton, Utah, 84015
FutureSearch Trials of Dallas, L.P.
Dallas, Texas, 75231
UTSW
Dallas, Texas, 75235
iResearch Atlanta
Decatur, Georgia, 30030
Collaborative Neuroscience Network, LLC
Garden Grove, California, 92845
Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois, 60169
Baylor College of Medicine
Houston, Texas, 77030
CNS Health care (Jacksonville)
Jacksonville, Florida, 32256
Altea Research
Las Vegas, Nevada, 89102
BTC of Lincoln
Lincoln, Rhode Island, 02865
Meridien Research
Maitland, Florida, 32751
Synergy San Diego
National City, California, 91950
Manhattan Behavioral Medicine
New York, New York, 10036
Pacific Research Partners, LLC
Oakland, California, 94607
IPS Research
Oklahoma City, Oklahoma, 73103
Rivus Wellness & Research Institute
Oklahoma City, Oklahoma, 73112
CNS Health care (Orlando)
Orlando, Florida, 32801
UPenn
Philadelphia, Pennsylvania, 19104
Summit Research Network (Oregon)
Portland, Oregon, 97210
Pillar Clinical Research
Richardson, Texas, 75080
Finger Lakes Clinical Research
Rochester, New York, 14618
Woodland Research Northwest
Rogers, Arkansas, 72758
Schuster Medical Research Institute
Sherman Oaks, California, 91403
St. Louis Clinical Trials
St Louis, Missouri, 63141
Viking Clinical Research
Temecula, California, 92591
Collaborative Neuroscience Network, LLC
Torrance, California, 90502
Pacific Clinical Research Medical Group
Upland, California, 91786
IPC Research
Waukesha, Wisconsin, 53188
KUMC
Wichita, Kansas, 67214
About this study
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder
To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) and an inadequate response to antidepressant therapy
- Being tested
- Pimavanserin, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PimavanserinDrug
Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
PlaceboOther
Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
| Study group | Role | What they receive |
|---|---|---|
| Pimavanserin 34 mg + SSRI/SNRI | Experimental | Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study. Receives: Drug: Pimavanserin |
| Placebo + SSRI/SNRI | Placebo comparator | Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Week 5 in the HAMD-17 Total Score
The Hamilton Rating Scale for Depression (HAMD-17) is a 17-item scale to assess depression. The HAMD-17 consists of 8 items with a score on a 3 point scale and 9 items with a score on a 5 point scale. Each item is rated from least (0) to most frequent or most severe, as applicable, with highest scores of 2 to 4, depending on the item. Items are summed up to calculate the HAMD-17 total score. The total score ranges from 0 to 52. A higher total score indicates more severe depression.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Secondary outcomes (10)
Change From Baseline to Week 5 in the SDS Total Score
The Sheehan Disability Scale is a 3-item patient-facing questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point scale from 0 (no impairment) to 10 (most severe). The total SDS score ranges from 0 to 10. It is calculated as the arithmetic mean of the scores for all 3 items. A higher score indicates greater disability.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Treatment Response and Remission Rates at the End of 5-week Treatment Period
The Hamilton Rating Scale for Depression (HAMD-17) is a 17-item scale to assess depression. Each item is rated from least (0) to most frequent or most severe, as applicable, with highest scores of 2 to 4 depending on the item. Items are summed up to calculate the HAMD-17 total score. A higher total score indicates more severe depression.
Treatment response was defined as a reduction from Baseline in HAMD-17 total score of >=50%.
Remission was defined as a HAMD-17 total score <=7.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in CGI-S Total Score
The Clinical Global Impression-Severity Scale is a 1-item scale, used to rate the severity of the disorder from 0 (not assessed) to 7 (among the most extremely ill patients). A higher CGI-I score denotes more severe depression.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
CGI-I Score at Week 5
The Clinical Global Impression- Improvement scale is a 1-item scale, used to rate the global improvement of the patient since beginning of the study from 0 (not assessed) to 7 (very much worse). A higher CGI-I score denotes less improvement in depression.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in SF-12 Score
The 12-Item Short Form Health Survey is a patient-reported outcome measure that addresses 8 domains of physical functioning, role - physical, bodily pain, general health perceptions, vitality, social functioning, role - emotional, and mental health. Composite scores were obtained representing physical health and mental health composite summaries, Physical Component Summary (PCS) and Mental Component Summary (MCS), respectively. An algorithm was used to generate PCS and MCS for comparison to normative data. In normative data, the mean score was set to 50; thus, scores >50 indicate better physical or mental health than the mean and scores <50 indicate worse health. A higher score is indicative of a better health state.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in DAI-10 Score
The Drug Attitude Inventory-10 is a 6-item patient-facing questionnaire to evaluate a patient's perceptions and experiences of treatment. It contains 6 items that a patient who is fully adherent to prescribed medication would answer as "True," and 4 items that a patient who is fully adherent would rate as "False." Scores are allocated to each answer and the total score is calculated as the sum. A correct answer is scored +1 and an incorrect answer is scored -1. The total score ranges from -10 to 10 and is the sum of pluses and minuses. A positive total score indicates a positive subjective response (adherent) and a negative total score indicates a negative subjective response (nonadherent). Higher scores denoted better adherence.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in KSS Score
The Karolinska Sleepiness Scale is a patient-facing 1-item scale that measures the patient's drowsiness. Scoring is based on a 9-point verbally anchored scale ranging from "extremely alert" (1) to "very sleepy, great effort to keep awake, fighting sleep" (9). Higher scores denote more drowsiness.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in MGH-SFI Score
The Massachusetts General Hospital Sexual Functioning Index is a patient-facing questionnaire that quantifies sexual dysfunction into 5 functional domains ("interest in sex," "sexual arousal," "ability to achieve orgasm," "ability to maintain erection" [males only], and "sexual satisfaction"). Patients rate each item using a 6-point scale ranging from 1 (good function) to 6 (poor function). The MGH-SFI score is calculated as the arithmetic mean of the item scores for the 5 domains. The mean MGH-SFI score ranges from a minimum value of 1 to a maximum value of 6. Higher scores denotes worse sexual dysfunction.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in BIS-11 Score
The Barratt Impulsiveness Scale-11 is a questionnaire for assessment of the personality/behavioral construct of impulsiveness. It is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale from Rarely/Never (1) to Almost Always/Always (4). Items are summed up to calculate the total score. The BIS-11 total score ranges from 30 to 120. Higher scores denotes more impulsiveness.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in SIS Score
The Sheehan Irritability Scale is a 7-item patient-reported outcome measure to measure the frequency, severity, and impairment associated with irritability in psychiatric patients. It includes items on: irritability, frustration, edginess/ impatience/ overreaction, moodiness, anger with self, anger with others, and temper. Items are answered on an 11-point rating scale where higher scores indicated greater severity (0=not at all, 10=extremely). Item responses are summed into a total score (range=0-70). Higher scores mean higher irritability.
Measured: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2017 (estimated)
- Study startDec 2016
- Primary completionSep 2018
- Study completionOct 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Adjunctive Treatment of Major Depressive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 207 participants (actual)
Sponsor and investigators
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03018340
- Sponsor's protocol ID
- ACP-103-042
- Status last verified
- Oct 2019
- First submitted
- 10 Jan 2017
- Last updated
- 14 Nov 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Jha MK, Fava M, Freeman MP, Thase ME, Papakostas GI, Shelton RC, Trivedi MH, Dirks B, Liu K, Stankovic S. Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY. J Clin Psychiatry. 2020 Dec 1;82(1):20m13425. doi: 10.4088/JCP.20m13425.
PubMed 33264819Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). J Clin Psychiatry. 2019 Sep 24;80(6):19m12928. doi: 10.4088/JCP.19m12928.
PubMed 31556975
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder
- ClinicalTrials.gov ID
- NCT03018340
- Acronym / sponsor ID
- ACP-103-042
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 207 participants (actual)
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry (pharma, biotech, devices)
- Study start
- Dec 2016 (actual)
- Primary completion
- Sep 2018 (actual)
- Study completion
- Oct 2018 (actual)
- First posted
- 12 Jan 2017 (estimated)
- Results
- Posted 14 Nov 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) and an inadequate response to antidepressant therapy
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pimavanserin 34 mg + SSRI/SNRI | Experimental | Drug: PimavanserinDrug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study. |
| Placebo + SSRI/SNRI | Placebo comparator | Other: PlaceboPlacebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Adult patients, aged 18 years and above
- A clinical diagnosis of major depressive disorder (MDD)
- Is being treated with one of the following SSRI or SNRI antidepressants as monotherapy:
- Has a history of inadequate response to antidepressant treatments
Key exclusion criteria (4 listed)
- Patient has a psychotic disorder other than MDD
- Patient has current evidence of a serious and/or unstable neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program
- Patient has a history or symptoms of long QT syndrome
- Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PimavanserinPimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study. | Drug | Pimavanserin 34 mg + SSRI/SNRI |
| PlaceboPlacebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study. | Other | Placebo + SSRI/SNRI |
Primary outcome
Change From Baseline to Week 5 in the HAMD-17 Total Score
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
The Hamilton Rating Scale for Depression (HAMD-17) is a 17-item scale to assess depression. The HAMD-17 consists of 8 items with a score on a 3 point scale and 9 items with a score on a 5 point scale. Each item is rated from least (0) to most frequent or most severe, as applicable, with highest scores of 2 to 4, depending on the item. Items are summed up to calculate the HAMD-17 total score. The total score ranges from 0 to 52. A higher total score indicates more severe depression.
10 secondary outcomes
Change From Baseline to Week 5 in the SDS Total Score
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Treatment Response and Remission Rates at the End of 5-week Treatment Period
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in CGI-S Total Score
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
CGI-I Score at Week 5
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in SF-12 Score
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in DAI-10 Score
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in KSS Score
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in MGH-SFI Score
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in BIS-11 Score
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Change From Baseline to Week 5 in SIS Score
Time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 33264819Jha MK, Fava M, Freeman MP, Thase ME, Papakostas GI, Shelton RC, Trivedi MH, Dirks B, Liu K, Stankovic S. Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY. J Clin Psychiatry. 2020 Dec 1;82(1):20m13425. doi: 10.4088/JCP.20m13425.
- Derived from this study: PubMed 31556975Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). J Clin Psychiatry. 2019 Sep 24;80(6):19m12928. doi: 10.4088/JCP.19m12928.
- Individual participant dataSharing planned: No
Related trials for Adjunctive Treatment of Major Depressive Disorder
RecruitingPhase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Depressive Disorder, Major
RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Depressive Disorder, Major
RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Depressive Disorder, Major
RecruitingPhase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
RecruitingPhase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
36 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Pimavanserin in people with Adjunctive Treatment of Major Depressive Disorder, run by ACADIA Pharmaceuticals Inc. at 36 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 36 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 Nov 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Week 5 in the HAMD-17 Total Score (time frame: Baseline, 5 weeks and 10 weeks during Stage 1 and Stage 2, respectively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03018340, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2019.